Related Experiment Videos
Development of the membrane autotransfusion system prototype-II: MATS-II
K Fukunaga1, T Shimoyama, K Sawada
1Department of Internal Medicine IV, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Artificial Organs
|May 18, 2000
Summary
The membrane autotransfusion system (MATS-II) effectively concentrates blood, preserving over 90% of red blood cells and platelets with minimal damage. This preclinical prototype meets clinical autotransfusion requirements.
Area of Science:
- Biomedical Engineering
- Medical Devices
- Cardiovascular Technology
Background:
- The first prototype (MATS-I) provided foundational experience for developing an improved system.
- Plasmapheresis technology is utilized in the membrane autotransfusion system (MATS).
Purpose of the Study:
- To evaluate the performance of the miniaturized, self-operative, preclinical prototype (MATS-II).
- To assess the MATS-II's efficacy in concentrating diluted blood with varying hematocrit levels.
Main Methods:
- Optimized blood filtration parameters and synchronized blood/flux pumps were integrated into a custom CPU-board for MATS-II.
- The MATS-II was tested using diluted blood samples with different hematocrit concentrations.
Main Results:
- The device successfully concentrated 4,000-10,000 ml of blood with varying hematocrit levels to over 40% concentration.
- Flow speed was automatically controlled between 250-400 ml/min.
- No significant damage to red blood cells (RBC) was observed, and over 90% of platelets were salvaged alongside RBCs.
Conclusions:
- The MATS-II demonstrates efficient hemoconcentration with minimal cellular blood component damage.
- The preclinical prototype fulfills all clinical requirements for an autotransfusion device.